15236
N,O-双(三甲基硅基)氨基甲酸酯
≥98.0% (T)
别名:
BSC, 三甲基硅烷基 N-三甲基硅烷基氨基甲酸酯
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
(CH3)3SiNHCO2Si(CH3)3
化学文摘社编号:
分子量:
205.40
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
252-520-4
Beilstein/REAXYS Number:
2043399
MDL number:
Assay:
≥98.0% (T)
Form:
solid
产品名称
N,O-双(三甲基硅基)氨基甲酸酯, ≥98.0% (T)
InChI key
DGIJAZGPLFOQJE-UHFFFAOYSA-N
InChI
1S/C7H19NO2Si2/c1-11(2,3)8-7(9)10-12(4,5)6/h1-6H3,(H,8,9)
SMILES string
C[Si](C)(C)NC(=O)O[Si](C)(C)C
assay
≥98.0% (T)
form
solid
mp
77-83 °C
functional group
amine
Quality Level
正在寻找类似产品? 访问 产品对比指南
Other Notes
非常适于使醇、酚和羧酸甲硅烷基化的试剂。副产物仅为 CO2 和 NH3；可用于胺的甲硅氧基羰基化反应；以及由羧酰氯合成酰基异氰酸酯
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
法规信息
新产品
此项目有
M J Sorich et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 26(1), 13-21 (2014-08-15)
Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral oncogene (KRAS) exon 2 wild-type tumors. Recent evidence has suggested that other RAS mutations (in exons 3 and 4
Yoshitaka Narita et al.
Neuro-oncology, 21(3), 348-359 (2018-12-01)
We conducted a phase III trial of personalized peptide vaccination (PPV) for human leukocyte antigen (HLA)-A24+ recurrent glioblastoma to develop a new treatment modality. We randomly assigned 88 recurrent glioblastoma patients to receive PPV (n = 58) or the placebo
Sudarshan Chari et al.
PLoS genetics, 9(8), e1003661-e1003661 (2013-08-13)
The phenotypic outcome of a mutation cannot be simply mapped onto the underlying DNA variant. Instead, the phenotype is a function of the allele, the genetic background in which it occurs and the environment where the mutational effects are expressed.
L. Birkofer et al.
Journal of Organometallic Chemistry, 99, C1 (1975)
Ronak Saluja et al.
Journal of oncology practice, 14(5), e280-e294 (2018-03-31)
The purpose of this study was to determine if clinical benefits of novel anticancer drugs, measured by the ASCO Value Framework and European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale, have increased over time in parallel with
商品
Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持